Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERACTION OF DEXANABINOL (HU-211), A NOVEL NMDA RECEPTOR ANTAGONIST, WITH THE DOPAMINERGIC SYSTEM
Autore:
STRIEM S; BARJOSEPH A; BERKOVITCH Y; BIEGON A;
Indirizzi:
PHARMOS CORP IL-76326 REHOVOT ISRAEL PHARMOS CORP IL-76326 REHOVOT ISRAEL
Titolo Testata:
European journal of pharmacology
fascicolo: 3, volume: 338, anno: 1997,
pagine: 205 - 213
SICI:
0014-2999(1997)338:3<205:IOD(AN>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
INHIBIT ADENYLATE-CYCLASE; CLOSED-HEAD INJURY; CANNABINOID RECEPTOR; PARKINSONS-DISEASE; BRAIN-DAMAGE; RAT; ISCHEMIA; STRIATUM; NEUROTRANSMITTERS; METHAMPHETAMINE;
Keywords:
HU-211; NMDA RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR ANTAGONIST; CATALEPSY; PARKINSONS DISEASE;
Tipo documento:
Article
Natura:
Periodico
Citazioni:
41
Recensione:
Indirizzi per estratti:
Citazione:
S. Striem et al., "INTERACTION OF DEXANABINOL (HU-211), A NOVEL NMDA RECEPTOR ANTAGONIST, WITH THE DOPAMINERGIC SYSTEM", European journal of pharmacology, 338(3), 1997, pp. 205-213

Abstract

The interaction of 7-hydroxy-Delta(6)-tetrahydrocannabinol 1,1-dimethylheptyl (Dexanabinol; HU-211), a novel NMDA receptor antagonist, withthe dopaminergic system was examined using in vitro and in vivo systems. HU-211 (50 or 100 mu M) inhibited the binding of -tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrochloride ([H-3] SCH-23390), a dopamine D-1 receptor antagonist, by 29.7 +/- 1.8% and 52.7 +/- 6.3%, respectively. HU-211 10 mu M, like the dopamine D-1 receptor agonist nyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride (SKF-38393), enhanced the conversion of [H-3]adenine to cyclic AMP (cAMP) (51.8 +/- 29.7% and 35.6 +/- 21.5% over control, respectively). The HU-211-induced increase was not inhibited by SCH-23390. HU-211 together with the dopamine D-1 receptor agonist caused a synergistic elevation (314.7 +/- 14.3%). HU-211 reduced the catalepsy induced by dopamine receptor antagonists. At 10 mg/kg, HU-211 significantly (P < 0.001) reducedthe catalepsy time induced by D-1, D-2 and non-selective dopamine receptor antagonists. Overall, the results of the present study demonstrate that HU-211 interacts with the dopaminergic system and enhances activity at the dopamine D-1 receptor level. This activity may have implications in diseases involving the dopaminergic system, such as Parkinson's disease. (C) 1997 Elsevier Science B.V.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 02:42:04